Clinical Trial Update: The Safety and Efficacy of Universal CAR-T Cells Targeting BCMA in the Treatment of Refractory NMOSD [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial sponsored by Bioray Laboratories is evaluating universal BCMA-targeting CAR-T cells for refractory neuromyelitis optica spectrum disord…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuromyelitis Optica Spectrum Disorder

Drugs mentioned

• universal BCMA-targeting CAR-T cells (CAR-T cells targeting BCMA)

Snippet

Sponsor: Bioray Laboratories | Conditions: Autoimmune Disease | Phase 1 | Status: NOT_YET_RECRUITING